Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture?

Area of Science:

• Osteoporosis treatment
• Pharmacological interventions
• Biomarker validation

Background:

• Anti-resorptive agents are used for osteoporosis.
• Quantifying relationships between fracture endpoints and surrogates like bone mineral density (BMD) and bone turnover markers is of increasing interest.
• Statistical methodology is critical for assessing surrogate validity.

Purpose of the Study:

• To review definitions and statistical validation requirements for surrogate endpoints.
• To evaluate if BMD meets these requirements as a surrogate for fracture.
• To discuss the strengths and limitations of various statistical methods.

Main Methods:

• Review of definitions and statistical validation requirements for surrogate endpoints.
• Evaluation of BMD as a surrogate for fracture.
• Discussion of statistical methods, including individual patient data analyses and meta-regression.

Main Results:

• BMD is correlated with fracture risk, identifying patients who may need treatment.
• Analyses of individual patient data suggest limited anti-fracture efficacy explained by BMD increases for certain agents (e.g., alendronate, risedronate, raloxifene).
• Meta-regression analyses using summary statistics indicate that BMD improvements account for most anti-fracture benefits.

Conclusions:

• BMD is useful for identifying patients requiring osteoporosis treatment.
• There is limited evidence supporting BMD increases with anti-resorptive agents as a reliable substitute for fracture risk reduction.
• Caution is advised when interpreting disparate results from different statistical methods and study designs.